Abiomed Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Abiomed Stock Forecast and Price Target
The average target price for Abiomed's stock set by renowned analysts in recent months is $44.10, representing a potential downside of approximately -88.33% from its last closing price if met by 2025. This estimation is based on a high estimate of $49.39 and a low estimate of $39.25. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?
-88.33% Downside
Abiomed Fair Value Forecast for 2023 - 2025 - 2030
In the last year, Abiomed's Price has grown, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $109.05 – an increase of 100.00%. For the next six years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$106.86 | Buy/Sell | $118.92 | 18.38% |
| BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$73.26 | Buy/Sell | $70.14 | 9.20% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.25 | Buy/Sell | $92.47 | 20.50% |
| EW Stock Forecast | Edwards Lifesciences Corp | Outperform |
11
|
$88.01 | Buy/Sell | $91.18 | 10.21% |
| TFX Stock Forecast | Teleflex Inc | Hold |
13
|
$206.71 | Buy/Sell | $263.46 | 28.20% |
Abiomed Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Abiomed's Revenue has grown, rising from $840.88M to $1.03B – a growth of 22.70%. In the next year, analysts believe that Revenue will reach $1.58B – an increase of 53.59%. For the next six years, the forecast is for Revenue to grow by 70.52%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MMSI Stock Forecast | Merit Medical Systems | Outperform |
14
|
$73.38 | Buy/Sell | $89.25 | 19.92% |
| HAE Stock Forecast | Haemonetics | Outperform |
16
|
$87.66 | Buy/Sell | $70.17 | 19.78% |
| ITGR Stock Forecast | Integer Holdings | Outperform |
16
|
$111.15 | Buy/Sell | $95.00 | 16.96% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IART Stock Forecast | Integra LifeSciences Holdings | Hold |
16
|
$28.41 | Buy/Sell | $46.60 | 53.12% |
| ICUI Stock Forecast | ICU Medical | Outperform |
16
|
$94.53 | Buy/Sell | $153.50 | 44.40% |
| CNMD Stock Forecast | CONMED | Outperform |
16
|
$61.90 | Buy/Sell | $123.38 | 39.74% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LMAT Stock Forecast | LeMaitre Vascular | Outperform |
18
|
$62.99 | Buy/Sell | $59.86 | 11.13% |
| NVRO Stock Forecast | Nevro | Hold |
6
|
$11.62 | Buy/Sell | $21.34 | 37.69% |
| STXS Stock Forecast | Stereotaxis | Buy |
7
|
$2.35 | Buy/Sell | $4.25 | 91.49% |
Abiomed EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Abiomed's EBITDA has grown by 5.52%, rising from $269.07M to $283.93M. For the next year, analysts predict that EBITDA will reach $441.18M – an increase of 55.38%. Over the next six years, experts believe that Abiomed's EBITDA will grow at a rate of 31.29%.
Abiomed EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Abiomed's EBIT has grown, moving from $248.64M to $255.84M – an increase of 2.90%. In the next year, analysts predict that EBIT will jump to $457.80M – up 78.94% from the current level. Looking ahead to six years, experts forecast that EBIT will grow by 95.71%.
Abiomed EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, Abiomed's EPS has grown, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $7.27 – an increase of 100.00%. For the next six years, the forecast is for EPS to grow by 100.00%.
.jpg)